

## HR 5423

### GEDI Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 2, 2018

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Apr 2, 2018)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/5423>

### Sponsor

**Name:** Rep. Engel, Eliot L. [D-NY-16]

**Party:** Democratic • **State:** NY • **Chamber:** House

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Apr 2, 2018
Rep. McCollum, Betty [D-MN-4]	D · MN		Apr 2, 2018
Rep. Pocan, Mark [D-WI-2]	D · WI		Apr 2, 2018
Rep. Roybal-Allard, Lucille [D-CA-40]	D · CA		Apr 2, 2018

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Apr 2, 2018

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
115 S 3660	Related bill	Nov 27, 2018: Read twice and referred to the Committee on Finance.
115 HR 5942	Related bill	Oct 19, 2018: Referred to the Subcommittee on Health, Employment, Labor, and Pensions.

## **Gestational Diabetes Act of 2018 or the GEDI Act**

This bill amends the Public Health Service Act to direct the Centers for Disease Control and Prevention (CDC) to develop a multisite gestational diabetes research project to expand and enhance surveillance data and public health research on gestational diabetes.

The CDC must expand and intensify public health research on gestational diabetes.

The CDC must: (1) award grants for demonstration projects to reduce the incidence of gestational diabetes, the recurrence of such disease in subsequent pregnancies, and the development of type 2 diabetes in women with a history of gestational diabetes; and (2) work with state and Indian tribal-based diabetes prevention and control programs assisted by the CDC to encourage postpartum follow-up after gestational diabetes to reduce the incidence of gestational diabetes and its recurrence, the development of type 2 diabetes in at-risk women, and related complications.

## **Actions Timeline**

---

- **Apr 2, 2018:** Introduced in House
- **Apr 2, 2018:** Referred to the House Committee on Energy and Commerce.